Growth Metrics

Biogen (BIIB) Gross Profit (2016 - 2026)

Biogen has reported Gross Profit over the past 18 years, most recently at $1.8 billion for Q1 2026.

  • For Q1 2026, Gross Profit rose 0.84% year-over-year to $1.8 billion; the TTM value through Mar 2026 reached $7.5 billion, up 1.11%, while the annual FY2025 figure was $7.5 billion, 1.64% up from the prior year.
  • Gross Profit for Q1 2026 was $1.8 billion at Biogen, up from $1.8 billion in the prior quarter.
  • Over five years, Gross Profit peaked at $2.4 billion in Q4 2022 and troughed at $1.7 billion in Q1 2024.
  • A 5-year average of $2.0 billion and a median of $1.9 billion in 2023 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: decreased 20.23% in 2023 and later grew 6.34% in 2025.
  • Year by year, Gross Profit stood at $2.4 billion in 2022, then dropped by 6.63% to $2.2 billion in 2023, then dropped by 15.8% to $1.9 billion in 2024, then fell by 4.67% to $1.8 billion in 2025, then rose by 1.84% to $1.8 billion in 2026.
  • Business Quant data shows Gross Profit for BIIB at $1.8 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.9 billion in Q3 2025.